| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
MISSISSAUGA, Ontario—The morning of Jan. 30 saw Valeant Pharmaceuticals International Inc. announce that it has withdrawn its offer to acquireISTA Pharmaceuticals Inc. for $7.50 per share in cash—a transaction that would have carried a total equity value of approximately $360 million.
 
Valeant had previously announced that the offer would remain open until Jan. 31, 2012, but withdrew the offer a day early "due to lack of progress."
 
"Aswe stated last December, we were not interested in participating in alengthy evaluation process and we are disappointed that the ISTA teamwas not willing to fully explore our proposal by Jan. 31," stated J. Michael Pearson,chairman and CEO of Valent. "We continue to be disciplinedon our M&A strategy and we are actively working on otheropportunities that we believe can create value for our shareholders. Wewish the ISTA team well in their future endeavors."
 
Irvine, Calif.-based ISTA notes in its own official statement that it is talking multiple parties "that have expressed an interest in pursuing a strategic transaction," and adding that it "remains committed to maximizing shareholder value."

"Werepeatedly offered Valeant the opportunity to participate in ourstrategic review process on a level playing field with others, but itwas clear Valeant was only interested in an approach that would haveeffectively excluded others," Vincente Anido Jr., ISTA's CEO, said in thestatement. "We informed Valeant that there were simply too many othercompanies that had indicated strong interest in ISTA for us to take thatapproach."

Valeant had initially made a $6.50-per-share offer in December, which would have valued ISTA at roughly  $314 million, then raised its offer by a dollar per share on Jan. 17.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue